scholarly journals One-Year Changes in Symptoms of Depression and Weight in Overweight/Obese Individuals With Type 2 Diabetes in the Look AHEAD Study

Obesity ◽  
2012 ◽  
Vol 20 (4) ◽  
pp. 783-793 ◽  
Author(s):  
Lucy F. Faulconbridge ◽  
Thomas A. Wadden ◽  
Richard R. Rubin ◽  
Rena R. Wing ◽  
Michael P. Walkup ◽  
...  
Obesity ◽  
2012 ◽  
Vol 20 (8) ◽  
pp. 1675-1682 ◽  
Author(s):  
Inga Peter ◽  
Jeanne M. McCaffery ◽  
Alyson Kelley‐Hedgepeth ◽  
Hakon Hakonarson ◽  
Steven Reis ◽  
...  

2021 ◽  
Author(s):  
Ariana M. Chao ◽  
Thomas A. Wadden ◽  
Jeanne M. Clark ◽  
Kathleen M. Hayden ◽  
Marjorie J. Howard ◽  
...  

<strong>Objective:</strong> To evaluate changes in the prevalence of depressive symptoms, loneliness, and insomnia among older adults with type 2 diabetes from 2016 to 2020, and to assess risk factors for these conditions including demographics, multimorbidity, body mass index, treatment group, and pre-COVID-19 measure scores. <p><strong>Research Design and Methods:</strong> This was a prospective, observational study of participants from the Look AHEAD cohort study. Data were from two assessments before COVID-19 (Visit 1 (V1): April 2016-June 2018 and Visit 2 (V2): February 2018-February 2020), and one assessment during COVID-19 (Visit 3 (V3): July-December 2020). Surveys were administered to assess depressive symptoms, loneliness, and insomnia. </p> <p><strong>Results:</strong> The study included 2829 adults (63.2% female, 60.6% white, mean [SD] age 75.6 [6.0] years). The prevalence of mild or greater depressive symptoms did not change significantly between the two pre-pandemic visits (p=0.88) but increased significantly from pre- to during COVID-19 (19.3% at V2 to 30.4% at V3 (p<0.001)). Higher odds of mild or greater depressive symptoms at V3 were associated with being female (adjusted odds ratio [OR]=1.4; 95% CI, 1.1-1.7), identifying as non-Hispanic White (OR=1.4; 95% CI, 1.1-1.7), having obesity (OR=1.3; 95% CI, 1.0-1.5), and reporting mild or greater depressive symptoms at Visit 1 (OR=4.0; 95% CI, 2.9-5.4), V2 (OR=4.4; 95% CI, 3.2-5.9), or both visits (OR=13.4; 95% CI, 9.7-18.4). The prevalence of loneliness increased from 12.3% at V1 to 22.1% at V3 (p<0.001), while the prevalence of insomnia remained stable across visits at 31.5-33.3%. </p> <p><strong>Conclusions:</strong> The prevalence of mild or greater depressive symptoms in older adults with diabetes was more than 1.6 times higher during COVID-19 than before the pandemic. </p>


Diabetes Care ◽  
2021 ◽  
pp. dc211179
Author(s):  
Ariana M. Chao ◽  
Thomas A. Wadden ◽  
Jeanne M. Clark ◽  
Kathleen M. Hayden ◽  
Marjorie J. Howard ◽  
...  

2021 ◽  
Author(s):  
Ariana M. Chao ◽  
Thomas A. Wadden ◽  
Jeanne M. Clark ◽  
Kathleen M. Hayden ◽  
Marjorie J. Howard ◽  
...  

<strong>Objective:</strong> To evaluate changes in the prevalence of depressive symptoms, loneliness, and insomnia among older adults with type 2 diabetes from 2016 to 2020, and to assess risk factors for these conditions including demographics, multimorbidity, body mass index, treatment group, and pre-COVID-19 measure scores. <p><strong>Research Design and Methods:</strong> This was a prospective, observational study of participants from the Look AHEAD cohort study. Data were from two assessments before COVID-19 (Visit 1 (V1): April 2016-June 2018 and Visit 2 (V2): February 2018-February 2020), and one assessment during COVID-19 (Visit 3 (V3): July-December 2020). Surveys were administered to assess depressive symptoms, loneliness, and insomnia. </p> <p><strong>Results:</strong> The study included 2829 adults (63.2% female, 60.6% white, mean [SD] age 75.6 [6.0] years). The prevalence of mild or greater depressive symptoms did not change significantly between the two pre-pandemic visits (p=0.88) but increased significantly from pre- to during COVID-19 (19.3% at V2 to 30.4% at V3 (p<0.001)). Higher odds of mild or greater depressive symptoms at V3 were associated with being female (adjusted odds ratio [OR]=1.4; 95% CI, 1.1-1.7), identifying as non-Hispanic White (OR=1.4; 95% CI, 1.1-1.7), having obesity (OR=1.3; 95% CI, 1.0-1.5), and reporting mild or greater depressive symptoms at Visit 1 (OR=4.0; 95% CI, 2.9-5.4), V2 (OR=4.4; 95% CI, 3.2-5.9), or both visits (OR=13.4; 95% CI, 9.7-18.4). The prevalence of loneliness increased from 12.3% at V1 to 22.1% at V3 (p<0.001), while the prevalence of insomnia remained stable across visits at 31.5-33.3%. </p> <p><strong>Conclusions:</strong> The prevalence of mild or greater depressive symptoms in older adults with diabetes was more than 1.6 times higher during COVID-19 than before the pandemic. </p>


Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 170-OR
Author(s):  
JINGYI QIAN ◽  
MICHAEL P. WALKUP ◽  
SHYH-HUEI CHEN ◽  
PETER H. BRUBAKER ◽  
DALE BOND ◽  
...  

2022 ◽  
Author(s):  
John M. Jakicic ◽  
Robert I. Berkowitz ◽  
Paula Bolin ◽  
George A. Bray ◽  
Jeanne M. Clark ◽  
...  

OBJECTIVE: To conduct <i>post-hoc</i> secondary analysis examining the association between change in physical activity (PA), measured with self-report and accelerometry, from baseline to 1 and 4 years and cardiovascular disease (CVD) outcomes in the Look AHEAD Trial. <p>RESEARCH DESIGN AND METHODS: Participants were adults with overweight/obesity and type 2 diabetes with PA data at baseline and year 1 or 4 (n = 1,978). Participants were randomized to diabetes support and education or intensive lifestyle intervention. Measures included accelerometry-measured moderate-to-vigorous PA (MVPA), self-reported PA, and composite (morbidity and mortality) CVD outcomes.</p> <p>RESULTS: In pooled analyses of all participants, using Cox proportional hazards models, each 100 MET-min/wk increase in accelerometry-measured MVPA from baseline to 4 years was associated with decreased risk of the subsequent primary composite outcome of CVD. Results were consistent for changes in total MVPA [HR=0.97 (95% CI: 0.95, 0.99)] and MVPA accumulated in <u>></u>10-minute bouts [HR=0.95 (95% CI: 0.91, 0.98)], with a similar pattern for secondary CVD outcomes. Change in accelerometry-measured MVPA at 1 year and self-reported change in PA at 1 and 4 years were not associated with CVD outcomes.</p> <p>CONCLUSIONS: Increased accelerometry-measured MVPA from baseline to year 4 is associated with decreased risk of CVD outcomes. This suggests the need for long-term engagement in MVPA to reduce the risk of CVD in adults with overweight/obesity and type 2 diabetes.</p>


Diabetes Care ◽  
2011 ◽  
Vol 34 (10) ◽  
pp. 2152-2157 ◽  
Author(s):  
J. L. Unick ◽  
D. Beavers ◽  
J. M. Jakicic ◽  
A. E. Kitabchi ◽  
W. C. Knowler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document